Research Agreement Sample Contracts

Smart Energy Solutions Inc – Research Agreement With Yissum (August 9th, 2018)
Smart Energy Solutions Inc – Research Agreement (May 25th, 2018)

This Research Agreement (the "Agreement"), is made and entered into on May 2, 2018, between Canna Powder Ltd, of 20 Raul Wallenberg, Tel -Aviv, Israel (the "Company") and Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd. with its registered address at Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel ("Yissum").

Alcobra Ltd. – Coversheet Research Agreement (May 14th, 2018)

Arcturus Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, USA and having its registered office at 10628 Science Center Drive Suite 200, San Diego, California 92121, USA ("Arcturus") and Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized and existing under the laws of Delaware and having it registered office at 40 Landsdowne Street. Cambridge, MA 02139 ("Takeda") agree as follows:

Corporate Research Agreement (March 13th, 2018)

THIS AGREEMENT is entered into as of the 1. day of August, 2017 (the "Effective Date"), by and between RENOVACARE INC., a corporation organized under the laws of the State of New York, and having an office at 430 Park Avenue, Suite 702 New York, NY 10022 (the "Company"), and the UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, a non-profit, state-related educational institution incorporated under the laws of the Commonwealth of Pennsylvania and having an office at Office of Research, 123 University Place, Pittsburgh, Pennsylvania 15213 (the "University").

Lexaria Corp – National Research Council Conseil National De Recherches Master Collaborative Canada Canada Research Agreement (January 5th, 2018)

WHEREAS the Parties have common interests in the development of specialty and functional ingredients for differentiated consumer markets involving functional food, nutrition, and health and wellness applications;

Generex Biotechnology Corporation – License and Research Agreement (December 12th, 2017)

This License and Research Agreement (the "Agreement"), effective as of the day of November, 2017 (the "Effective Date"), is by and between Antigen Express, Inc., a wholly-owned subsidiary of Generex Biotechnology Corporation, a Delaware corporation, with an address of 4145 North Service Road, Suite 200, Burlington, Ontario, Canada L7L 6A3 (hereinafter referred as "Licensor"), and Shenzhen BioScien Pharmaceuticals Co., Ltd., located at Room 311, First Building, Shenzhen Overseas Venture Park (Longgang), Shenzhen 518116, Guangdong, China (hereinafter referred to as "Licensee"). Licensor and Licensee may each be referred to herein individually as a "Party" and collectively

Nivalis Therapeutics, Inc. – License and Research Agreement (October 24th, 2017)

This License and Research Agreement (the Agreement) is effective as of October 26, 2015 (the Effective Date) by and between ALPINE IMMUNE SCIENCES, INC., a Delaware corporation located at 600 Stewart Street, Suite 1503, Seattle, WA 98101 (Alpine), and KITE PHARMA, INC., a Delaware corporation located at 2225 Colorado Avenue, Santa Monica, CA 90404 (Kite). Alpine and Kite are referred to individually as a Party and collectively as the Parties.

Nivalis Therapeutics, Inc. – License and Research Agreement Amendment No. 1 (October 24th, 2017)

This License and Research Agreement Amendment No. 1 (this Amendment No. 1) is made effective as of October 20, 2017 (the Amendment Effective Date) by and between AIS Operating Co., Inc., f/k/a Alpine Immune Sciences, Inc., a Delaware corporation (Alpine), and Kite Pharma, Inc., a Delaware corporation (Kite), with reference to the following facts:

Research Agreement (September 13th, 2017)

THIS AGREEMENT effective this 16 day of Aug, 2017, by and between BioSolar Inc., (hereinafter referred to as "Sponsor") and North Carolina Agricultural and Technical State University, a constituent member of the University of North Carolina system (hereinafter referred to as "University"); individually referred to as "Party" or collectively as "Parties".

IASO BioMed, Inc. – Amendment to the Research Agreement Between Iaso Biomed Us Inc., and the Research Institute of the McGill University Health Centre (March 24th, 2017)

This Amendment Number One (this "Amendment"), effective January 8, 2017, to the Research Agreement between IASO Biomed, Inc., and the Research institute of the McGill University Health Centre, effective January 8, 2016,

StemCells, Inc. – Contract Research Agreement (March 21st, 2017)

This Contract Research Agreement is entered into as of this __ day of _________, 2017 (the "Effective Date"), by and between The Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 ("University") and Microbot Medical Ltd., a company formed under the laws of Israel, with offices at 5 Hamada Street, Yokneam, Israel (the "Company").

AVRA Medical Robotics, Inc. – Research Agreement (February 14th, 2017)

This research agreement ("Agreement") is made and entered into by and between AVRA Medical Robotics, lnc. ("Company") and The University of Central Florida Board of Trustees ("UCF"), (individually, "Party", or collectively, "Parties").

Shuttle Pharmaceuticals, Inc. – SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM RESEARCH AGREEMENT AND SUBCONTRACT BETWEEN GEORGETOWN UNIVERSITY AND SHUTTLE PHARMACEUTICALS, LLC. PURSUANT TO AWARD NUMBER HHSN261201600027C - NCI CONTROL NUMBER:N43CO-2016-00027 ("Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation Late Effect") (February 13th, 2017)

In consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, and intending to be legally bound, the parties expressly agree to the terms and conditions contained in this Agreement.

IASO BioMed, Inc. – Research Agreement (February 1st, 2017)

THIS AGREEMENT, effective as of the date of the last duly authorized signature below (the "Effective Date"), is entered into by and among IASO BioMed, Inc., with a place of business located at 7315 East Peakview Avenue, Centennial, Colorado 80111 ("IASO BioMed, Inc."), The Research Institute of the McGill University Health Centre, with an address of 2155 Guy Street, Suite 500, Montreal QC H3H 2R9 (the "Institution") and Dr. Vassilios Papadopoulos, with an address of The Research Institute of the McGill University Health Centre, 1001 Decarie Blvd., Bloc E, Montreal QC H4A 3J1 (the "Principal Investigator"), governing a research study entitled: "Peptide-based pharmacological induction of androgen formation in male hypogonadism" (the "Study" or "Research Program"), to be conducted by the Principal Investigator at the Institution. IASO BioMed, Inc., Institution, and Principal Investigator shall collectively be referred to as "parties" and individually as a "party".

OWC Pharmaceutical Research Corp. – Research Agreement (January 12th, 2017)

This Research Agreement ("Agreement") is made and entered into this 29th day of December, 2016, by and between One World Cannabis Ltd., a company duly incorporated under the laws of the State of Israel, having its registered office at 7 Imber Street, Petach Tikva, 4951141, Israel, by its authorized representative, Mr. Ziv Turner, CEO (the "Company")

Mymetics Corp – Research Agreement (December 1st, 2016)

Sanofi Pasteur Biologics, LLC, a Delaware limited liability corporation having a principal place of business at 38 Sidney St., Cambridge, MA 02139, USA ( together with its Affiliates "Sanofi Pasteur")

AMENDMENT NO. 1 DATED: JULY 21, 2016 TO ROUNDTABLE RESEARCH AGREEMENT EFFECTIVE June 16, 2016 BETWEEN NANOFLEX POWER CORPORATION (Hereinafter "Sponsor") AND THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Hereinafter "University") Reference: University of Michigan PG No. NOZ1732 (November 30th, 2016)

WHEREAS the Sponsor and University wish to change the terms of the Agreement to authorize the performance of Years 2 and 3 of the Project.

Roundtable Research Agreement (November 30th, 2016)

THIS AGREEMENT effective this 16 day of June, 2016, by and between NANOFLEX POWER CORPORATION (hereinafter "Sponsor") and the REGENTS OF THE UNIVERSITY OF MICHIGAN, a non-profit educational institution of the State of Michigan (hereinafter "University").

Roundtable Research Agreement (November 30th, 2016)

THIS AGREEMENT effective this 16 day of June, 2016, by and between NANOFLEX POWER CORPORATION (hereinafter "Sponsor") and the REGENTS OF THE UNIVERSITY OF MICHIGAN, a non-profit educational institution of the State of Michigan (hereinafter "University").

AMENDMENT NO. 1 DATED: JULY 21, 2016 TO ROUNDTABLE RESEARCH AGREEMENT EFFECTIVE June 16, 2016 BETWEEN NANOFLEX POWER CORPORATION (Hereinafter "Sponsor") AND THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Hereinafter "University") Reference: University of Michigan PG No. NO20568 (November 30th, 2016)

WHEREAS the Sponsor and University wish to change the terms of the Agreement to authorize the performance of Years 2 and 3 of the Project.

Research Agreement (November 8th, 2016)

THIS AGREEMENT effective this 16 day of Aug, 2016, by and between BioSolar Inc., (hereinafter referred to as "Sponsor") and North Carolina Agricultural and Technical State University, a constituent member of the University of North Carolina system (hereinafter referred to as "University"); individually referred to as "Party" or collectively as "Parties".

Checkpoint Therapeutics, Inc. – Research Agreement (July 11th, 2016)

THIS RESEARCH AGREEMENT (this "Agreement"), dated as of September 15th, 2015 (the "Effective Date"), between Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware Corporation (the "Company") having an address 3 Columbus Circle, 15th Floor, New York, NY 10019, and NeuPharma, Inc., a Delaware corporation ("NeuPharma") having an address of 1175 Chess Drive, Ste 206, Foster City, CA 94404.

Checkpoint Therapeutics, Inc. – Research Agreement (May 16th, 2016)

THIS RESEARCH AGREEMENT (this "Agreement"), dated as of September 15th, 2015 (the "Effective Date"), between Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware Corporation (the "Company") having an address 3 Columbus Circle, 15th Floor, New York, NY 10019, and NeuPharma, Inc., a Delaware corporation ("NeuPharma") having an address of 1175 Chess Drive, Ste 206, Foster City, CA 94404.

Kite Pharma, Inc. – License and Research AGREEMENT (February 29th, 2016)

This License and Research Agreement (the "Agreement") is effective as of October 26, 2015 (the "Effective Date") by and between Alpine Immune Sciences, Inc., a Delaware corporation located at 600 Stewart Street, Suite 1503, Seattle, WA 98101 ("Alpine"), and Kite Pharma, Inc., a Delaware corporation located at 2225 Colorado Avenue, Santa Monica, CA 90404 ("Kite"). Alpine and Kite are referred to individually as a "Party" and collectively as the "Parties".

OncoCyte Corp – Second Amendment to the Sponsored Research Agreement (November 23rd, 2015)

This SECOND AMENDMENT TO THE SPONSORED RESEARCH AGREEMENT (the "Second Amendment") is made as of the date of the last signature below (the "Second Amendment Effective Date"), by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a Pennsylvania nonprofit corporation located at 3601 Spruce Street, Philadelphia, PA 19104 ("Wistar"), and ONCOCYTE CORPORATION, a corporation organized under the laws of California, with a principal place of business located at 1301 Harbor Bay Parkway, Alameda, CA 94502 ("Sponsor"). Wistar and Sponsor shall be referred to herein individually as a "Party" and collectively as the "Parties."

Hypersolar Inc – Research Agreement (September 28th, 2015)

This Research Agreement ("Agreement") is entered into on this 16th day of February, 2012 by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California Constitutional corporation, on behalf of its Santa Barbara campus, hereinafter called "University," and, HyperSolar, Inc., a Nevada corporation, having a principal place of business at 629 State St. Santa Barbara, CA 93101, hereinafter called "Sponsor."

vTv Therapeutics Inc. – License and Research Agreement by and Between Calithera Biosciences Inc. And High Point Pharmaceuticals, Llc Transtech Pharma Llc Dated as of March 5, 2015 (July 23rd, 2015)

THIS LICENSE AND RESEARCH AGREEMENT is entered into this 5th day of March, 2015 (the Effective Date) by and between Calithera Bioscience Inc., a corporation organized under the laws of the State of Delaware, having a business address at 343 Oyster Point Blvd #200, South San Francisco, CA 94080 (Calithera), on the one hand, and High Point Pharmaceuticals, LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (HPP) and TransTech Pharma LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (TransTech and collectively with HPP, High Point), on the other hand.

vTv Therapeutics Inc. – License and Research Agreement by and Between Calithera Biosciences Inc. And High Point Pharmaceuticals, Llc Transtech Pharma Llc Dated as of March 5, 2015 (July 13th, 2015)

THIS LICENSE AND RESEARCH AGREEMENT is entered into this 5th day of March, 2015 (the Effective Date) by and between Calithera Bioscience Inc., a corporation organized under the laws of the State of Delaware, having a business address at 343 Oyster Point Blvd #200, South San Francisco, CA 94080 (Calithera), on the one hand, and High Point Pharmaceuticals, LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (HPP) and TransTech Pharma LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (TransTech and collectively with HPP, High Point), on the other hand.

Calithera Biosciences – License and Research Agreement by and Between Calithera Biosciences Inc. And High Point Pharmaceuticals, Llc Transtech Pharma Llc Dated as of March 5, 2015 (May 11th, 2015)

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Multicell Technologies – Research Agreement (April 14th, 2015)

This RESEARCH AGREEMENT (the "Agreement"), effective as of March 10, 2015 (the "Effective Date"), is made by and between Oxis Biotech, Inc., a Delaware corporation, having a place of business at 1407 North Beverly Drive, Beverly Hills, CA 90210 ("OXIS") and MultiCell Immunotherapeutics, Inc., a Delaware corporation, having a place of business at 68 Cumberland Street, Suite 301, Woonsocket, RI 02895 (hereinafter "MCIT").

Kraig Biocraft Laboratories, Inc – INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT Between Kraig Biocraft Laboratories, Inc. (SPONSOR) and the University of Notre Dame Du Lac (NOTRE DAME) (March 31st, 2015)
Synthemed – Dear Sirs Research Agreement -- Extension No. 3 (March 31st, 2015)

We refer to our recent discussions regarding the research agreement between The University Court of the University of Glasgow (the University) and Pathfinder, LLC (now a wholly owned subsidiary of Pathfinder Cell Therapy, Inc., previously known as SyntheMed, Inc.) (the Company) (contract no. 49974/1) dated 23 March 2009, as extended by way of an extension letters from the University to the Company dated 29 March 2011 and 19 April 2012 (the Research Agreement). Terms defined in the Research Agreement will have the same meaning where used herein.

Regen BioPharma Inc – Research Agreement (March 25th, 2015)

This agreement is entered into as of this 9th day of March 2015, by and between Human BioMolecular Research Institute, a Washington nonprofit corporation located at 5310 Eastgate Mall San Diego, CA 92121, hereinafter referred to as HBRI, and Regen Biopharma, Inc., (CC) a Nevada corporation located at 4700 Spring Street, St.304 La Mesa CA 91942, hereinafter referred to as TENANT, subleasor at HBRI.

Bio-Matrix Scientific Group – Research Agreement (March 25th, 2015)

This agreement is entered into as of this 9th day of March 2015, by and between Human BioMolecular Research Institute, a Washington nonprofit corporation located at 5310 Eastgate Mall San Diego, CA 92121, hereinafter referred to as HBRI, and Regen Biopharma, Inc., (CC) a Nevada corporation located at 4700 Spring Street, St.304 La Mesa CA 91942, hereinafter referred to as TENANT, subleasor at HBRI.

Oxis International – Research Agreement (March 13th, 2015)

This RESEARCH AGREEMENT (the "Agreement"), effective as of March 10, 2015 (the "Effective Date"), is made by and between Oxis Biotech, Inc., a Delaware corporation, having a place of business at 1407 North Beverly Drive, Beverly Hills, CA 90210 ("OXIS") and MultiCell Immunotherapeutics, Inc., a Delaware corporation, having a place of business at 68 Cumberland Street, Suite 301, Woonsocket, RI 02895 (hereinafter "MCIT").